TNFRSF18 and neoplasm: This platform not only kills tumor cells through PDT and PTT effects but also targets and depletes Tregs via the anti-GITR antibody, thereby eliminating tumor immunosuppression, inducing T cell activation, and generating a durable antitumor immune response.562 Due to the plasticity of the M2-TAMs, reprogramming macrophages from the M2 to the M1 phenotype within tumors represents a promising strategy for cancer therapy.